Double Bond Pharmaceutical
DBP International AB: Brazilian patent for Temodex / SI-053 is granted
Patent approval provides protection for the technology and the product in Brazil until at least 2036.
"This is an important milestone in the development of SI-053 to get product patented and this is very good news for the company especially now prior starting clinical trials", comments Igor Lokot, CEO of DBP. - "We also have other applications pending for additional important markets."
More about Temodex/SI-053: Temodex, which is a locally acting formulation of temozolomide developed by RI PCP in Minsk, Belarus, is registered for marketing as the first-line treatment of glioblastoma within Belarus since 2014. Temodex was acquired by DBP in autumn 2015 and is now being prepared under the name SI-053 to pass through all the tests and trials required for registration within the EU and globally. Video presentation: https://youtu.be/iweOQPq316o
This disclosure contains information that DBP is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 23-01-2024 07:30 CET.
| Datum | 2024-01-23, kl 07:30 |
| Källa | Cision |
Hej Serverägare! Har du problem med troll och spam? Nu finns möjligheten att sätta en liten avgift, t.ex. 20kr, på discord invites och därmed stoppa många återkommande troll samtidigt som du tjänar lite pengar. Kolla in Invite Paywall.